Teva Pharmaceutical Industries (Teva) has appointed Dipankar Bhattacharjee as president and CEO of its Global Generic Medicines Group, effective December 5, 2016.
Bhattacharjee, who has served as president and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur Olafsson, who will step down from his role and remain active with the company until officially retiring at the end of the first quarter of 2017. Bhattacharjee will be based in the US.
As president and CEO of Teva Generics Europe, Bhattacharjee has experience improving revenues and profitability, significantly increasing operating profit margins in the European generics business.
Under his leadership, Teva’s European business demonstrated consistent improvement in sales and profits, establishing Teva as one of the premier generics companies in Europe.
He has focused on improving and enhancing the European generics operations, leading a full European integration of Actavis Generics and overseeing successful new product launches.
“Dipankar has been an integral part of Teva's management team since he joined the Company in 2009, and we are fortunate to have someone with his experience to lead our generics business at this important time,” said Erez Vigodman, Teva’s president and CEO.
“Teva will benefit from Dipankar’s extensive experience in generics and specialty medicines, his financial and operational expertise and his deep understanding and appreciation for Teva’s culture of innovation and our outstanding people.
“As we continue to focus on integrating and realizing the value of the Actavis Generics transaction, which is progressing according to plan, Dipankar and his team will focus on generating organic growth through new launches and replenishing the pipeline through our industry-leading R&D, and drive efficiencies across the generics organization. I have been incredibly impressed by Dipankar’s work in Europe, and I am confident that his capabilities, proven track record and experience make him the right person for this global leadership role.”
Bhattacharjee said: “I am honored to lead the Global Generic Medicines Group, a business with a robust R&D pipeline, a talented team of employees, well-established relationships with business partners and customers and significant prospects for organic growth.
“With the integration of Actavis proceeding on schedule and the complementary US distribution capabilities provided by our recent acquisition of Anda, we have a matchless opportunity to add value in the US healthcare system, and in the fast-changing global generics marketplace. I look forward to working with the rest of the management team to strengthen our generics business and help position Teva to achieve its full potential.”
Teva Pharmaceutical Industries, US, Global Generic Medicines Group, Healthcare Risk management, Appointment, Dipankar Bhattacharjee, Sigurdur Olafsson